CaMK Modulators

Cat.No.	Product Name	Information	Product Use Citations	Product Validations
S9141	Berbamine	Berbamine (BA), a traditional Chinese medicine extracted from Berberis amurensis (xiaoboan), is a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity and also an inhibitor of NF-κB. This compound induces apoptosis in human myeloma cells and inhibits the growth of cancer cells by targeting Ca²⁺/calmodulin-dependent protein kinase II (CaMKII).	Vet Res, 2025, 56(1):37 Vet Microbiol, 2025, 301:110356 iScience, 2024, 27(10):110862
S3609	Berbamine dihydrochloride	Berbamine (BA, BBM) dihydrochloride, a traditional Chinese medicines extracted from Berberis amurensis (xiaoboan), is a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity and also an inhibitor of NF-κB. Berbamine (BA, BBM) dihydrochloride induces apoptosis in human myeloma cells and inhibits the growth of cancer cells by targeting Ca²⁺/calmodulin-dependent protein kinase II (CaMKII).	iScience, 2024, 27(10):110862 Eur J Pharmacol, 2024, S0014-2999(24)00322-4

Cat.No.

Product Name

Information

Product Use Citations

Product Validations

S9141

Berbamine

Berbamine (BA), a traditional Chinese medicine extracted from Berberis amurensis (xiaoboan), is a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity and also an inhibitor of NF-κB. This compound induces apoptosis in human myeloma cells and inhibits the growth of cancer cells by targeting Ca²⁺/calmodulin-dependent protein kinase II (CaMKII).

Vet Res, 2025, 56(1):37

Vet Microbiol, 2025, 301:110356

iScience, 2024, 27(10):110862

S3609

Berbamine dihydrochloride

Berbamine (BA, BBM) dihydrochloride, a traditional Chinese medicines extracted from Berberis amurensis (xiaoboan), is a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity and also an inhibitor of NF-κB. Berbamine (BA, BBM) dihydrochloride induces apoptosis in human myeloma cells and inhibits the growth of cancer cells by targeting Ca²⁺/calmodulin-dependent protein kinase II (CaMKII).

iScience, 2024, 27(10):110862

Eur J Pharmacol, 2024, S0014-2999(24)00322-4